Literature DB >> 35487216

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors.

Leonid Cherkassky1, Zhaohua Hou2, Alfredo Amador-Molina2, Prasad S Adusumilli3.   

Abstract

The success of chimeric antigen receptor (CAR) T cell therapy in solid tumors, unlike in hematologic malignancies, is limited by inadequate tumor infiltration and T cell dysfunction and exhaustion. Regional delivery of CAR T cells in patients with solid tumors is safe and feasible; promotes infiltration, proliferation, and trafficking; and ignites functionally persisting systemic immunity.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  adoptive cell therapy; chimeric antigen receptor (CAR) T cells; regional therapies; solid tumors cell therapy

Mesh：

Substances：

Year:  2022        PMID： 35487216      PMCID： PMC9197990          DOI： 10.1016/j.ccell.2022.04.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  14 in total

1.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.

Authors:  Steven C Katz; Rachel A Burga; Elise McCormack; Li Juan Wang; Wesley Mooring; Gary R Point; Pranay D Khare; Mitchell Thorn; Qiangzhong Ma; Brian F Stainken; Earle O Assanah; Robin Davies; N Joseph Espat; Richard P Junghans
Journal:  Clin Cancer Res       Date:  2015-04-07       Impact factor: 12.531

2.  Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.

Authors:  Katarzyna C Pituch; Jason Miska; Giedre Krenciute; Wojciech K Panek; Gina Li; Tania Rodriguez-Cruz; Meijing Wu; Yu Han; Maciej S Lesniak; Stephen Gottschalk; Irina V Balyasnikova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

Review 3.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

4.  Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.

Authors:  Prasad S Adusumilli; Leonid Cherkassky; Jonathan Villena-Vargas; Christos Colovos; Elliot Servais; Jason Plotkin; David R Jones; Michel Sadelain
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

5.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Christine E Brown; Darya Alizadeh; Renate Starr; Lihong Weng; Jamie R Wagner; Araceli Naranjo; Julie R Ostberg; M Suzette Blanchard; Julie Kilpatrick; Jennifer Simpson; Anita Kurien; Saul J Priceman; Xiuli Wang; Todd L Harshbarger; Massimo D'Apuzzo; Julie A Ressler; Michael C Jensen; Michael E Barish; Mike Chen; Jana Portnow; Stephen J Forman; Behnam Badie
Journal:  N Engl J Med       Date:  2016-12-29       Impact factor: 91.245

6.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.

Authors:  Leonid Cherkassky; Aurore Morello; Jonathan Villena-Vargas; Yang Feng; Dimiter S Dimitrov; David R Jones; Michel Sadelain; Prasad S Adusumilli
Journal:  J Clin Invest       Date:  2016-07-25       Impact factor: 14.808

7.  Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.

Authors:  Michael C Jensen; Julie R Park; Nicholas A Vitanza; Adam J Johnson; Ashley L Wilson; Christopher Brown; Jason K Yokoyama; Annette Künkele; Cindy A Chang; Stephanie Rawlings-Rhea; Wenjun Huang; Kristy Seidel; Catherine M Albert; Navin Pinto; Juliane Gust; Laura S Finn; Jeffrey G Ojemann; Jason Wright; Rimas J Orentas; Michael Baldwin; Rebecca A Gardner
Journal:  Nat Med       Date:  2021-07-12       Impact factor: 53.440

8.  Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.

Authors:  Johanna Theruvath; Elena Sotillo; Christopher W Mount; Claus Moritz Graef; Alberto Delaidelli; Sabine Heitzeneder; Louai Labanieh; Shaurya Dhingra; Amaury Leruste; Robbie G Majzner; Peng Xu; Sabine Mueller; Derek W Yecies; Martina A Finetti; Daniel Williamson; Pascal D Johann; Marcel Kool; Stefan Pfister; Martin Hasselblatt; Michael C Frühwald; Olivier Delattre; Didier Surdez; Franck Bourdeaut; Stephanie Puget; Sakina Zaidi; Siddhartha S Mitra; Samuel Cheshier; Poul H Sorensen; Michelle Monje; Crystal L Mackall
Journal:  Nat Med       Date:  2020-04-27       Impact factor: 53.440

9.  Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Authors:  Kristen M Hege; Emily K Bergsland; George A Fisher; John J Nemunaitis; Robert S Warren; James G McArthur; Andy A Lin; Jeffrey Schlom; Carl H June; Stephen A Sherwin
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

10.  CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.

Authors:  Bryan D Choi; Xiaoling Yu; Ana P Castano; Henia Darr; Daniel B Henderson; Amanda A Bouffard; Rebecca C Larson; Irene Scarfò; Stefanie R Bailey; Genevieve M Gerhard; Matthew J Frigault; Mark B Leick; Andrea Schmidts; Jason G Sagert; William T Curry; Bob S Carter; Marcela V Maus
Journal:  J Immunother Cancer       Date:  2019-11-14       Impact factor: 13.751
View more
  2 in total

1.  Advancing together and moving forward: Combination gene and cellular immunotherapies.

Authors:  Saul J Priceman; Waseem Cheema; Prasad S Adusumilli
Journal:  Mol Ther Oncolytics       Date:  2022-05-30       Impact factor: 6.311

Review 2.  Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions.

Authors:  Peng Zhang; Yang Zhang; Nan Ji
Journal:  Front Immunol       Date:  2022-07-07       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.